Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

August 05, 2016

Due to the absence of “global” solution to provide the pneumonia vaccine at an affordable price during emergencies, MSF had to pay more than 20 times the lowest global price to vaccinate more than 5000 children against the disease in Greece. Pfizer and GSK, the manufacturers of the vaccine, have refused to reduce the price of the vaccine. View external media.  


July 14, 2016

Pfizer and GlaxoSmithKline refuse to lower the price of their pneumonia vaccines, making it harder to treat refugee children in Greece and in other countries with vulnerable populations. MSF has vaccinated more than 5,000 refugee children across Greece. View external media.

April 27, 2016

MSF hands over global petition as volunteers place 2,500 flowers in front of Pfizer’s headquarters in New York, representing the number of kids who die of pneumonia each day.

March 11, 2016

New York/New Delhi—Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a "patent opposition" in India to block US pharmaceutical company Pfizer from patenting a pneumococcal conjugate vaccine, and ensure affordable access to this critical vaccine (PCV13). This is the first time a vaccine (biosimilar) patent has been challenged in India by a medical organization and, if successful, will make affordable versions of this lifesaving vaccine available to developing countries and humanitarian organizations.

November 18, 2015

The number of patients treated by Doctors Without Borders/Médecins Sans Frontières (MSF) on a weekly basis in the UN Protection of Civilians Camp (PoC) in Malakal, South Sudan, has tripled since June, as overcrowding and substandard living conditions in the camp continue to jeopardize people's health.

November 12, 2015

MSF dumps $17 million in fake cash at Pfizer’s New York HQ, the amount the company makes in one day of pneumonia vaccine sales.